M&A Deal Summary

Ligand Pharmaceuticals Acquires CyDex Pharmaceuticals

On January 26, 2011, Ligand Pharmaceuticals acquired life science company CyDex Pharmaceuticals for 31M USD

Acquisition Highlights
  • This is Ligand Pharmaceuticals’ 4th transaction in the Life Science sector.
  • This is Ligand Pharmaceuticals’ 6th largest (disclosed) transaction.
  • This is Ligand Pharmaceuticals’ 4th transaction in the United States.
  • This is Ligand Pharmaceuticals’ 1st transaction in Kansas.

M&A Deal Summary
Date 2011-01-26
Target CyDex Pharmaceuticals
Sector Life Science
Buyer(s) Ligand Pharmaceuticals
Deal Type Add-on Acquisition
Deal Value 31M USD

Target

CyDex Pharmaceuticals

Lenexa, Kansas, United States
CyDex Pharmaceuticals, Inc. is a specialty pharmaceutical company developing products and licensing its Captisol technology. Captisol is currently incorporated in five FDA-approved medications and marketed by three of the company's licensees: Pfizer, Bristol-Myers Squibb and Prism Pharmaceuticals.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Ligand Pharmaceuticals

Jupiter, California, United States
Category Company
Founded 1987
Sector Life Science
Employees58
Revenue 131M USD (2023)
DESCRIPTION

Ligand Pharmaceuticals is a pharmaceutical company, develops products for men's and women's hormone-related diseases, osteoporosis, metabolic disorders, and cardiovascular and inflammatory diseases. Ligand Pharmaceuticals was founded in 1987 and is based in Jupiter, Florida.

DEAL STATS #
Overall 4 of 16
Sector (Life Science) 4 of 15
Type (Add-on Acquisition) 4 of 13
State (Kansas) 1 of 1
Country (United States) 4 of 14
Year (2011) 1 of 1
Size (of disclosed) 6 of 14
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2009-10-27 Metabasis Therapeutics

La Jolla, California, United States

Metabasis Therapeutics, Inc. is a biopharmaceutical company that has discovered novel drugs for metabolic diseases using its proprietary technology and its knowledge of processes and pathways within the liver that are useful for liver-selective drug targeting and treatment of metabolic diseases.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2015-12-17 Open Monoclonal Technology

Palo Alto, California, United States

Open Monoclonal Technology, Inc. (OMT) is a biotechnological company provides genetic engineering of animals for discovery of human therapeutic antibodies, naturally optimized human antibodies® and the only company with three transgenic animal platforms, collectively known as OmniAb™. All OmniAb platforms — OmniRat®, OmniMouse®, and OmniFlic™ — have broad freedom to operate, are protected by new patents and patent applications, and are available for all targets and indications

Buy $178M
Mergr

Product

Company

Legal